BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Montero N, Oliveras L, Soler MJ, Cruzado JM. Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clin Kidney J 2022;15:5-13. [PMID: 35265335 DOI: 10.1093/ckj/sfab131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cure E, Sirin H, Cure MC, Sahin DA. Dapagliflozin-induced long-term and severe anorexia and weight loss: An extraordinary case. Indian J Pharmacol 2021;53:174-5. [PMID: 34100404 DOI: 10.4103/ijp.IJP_785_19] [Reference Citation Analysis]
3 Cure E, Sirin H, Cure MC, Sahin DA. Dapagliflozin-induced long-term and severe anorexia and weight loss: An extraordinary case. Indian J Pharmacol 2021;53:174-5. [PMID: 34100404 DOI: 10.4103/ijp.IJP_785_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yang M, Shi FH, Liu W, Zhang MC, Feng RL, Qian C, Ma J. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model.Front Endocrinol (Lausanne). 2020;11:635. [PMID: 33312157 DOI: 10.3389/fendo.2020.00635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]